Contineum Therapeutics, Inc. $CTNM Shares Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP lifted its holdings in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 123.8% during the 2nd quarter, Holdings Channel reports. The firm owned 60,541 shares of the company’s stock after buying an additional 33,487 shares during the period. Seven Fleet Capital Management LP’s holdings in Contineum Therapeutics were worth $992,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in CTNM. Dynamic Technology Lab Private Ltd acquired a new position in shares of Contineum Therapeutics in the first quarter valued at approximately $118,000. Strs Ohio purchased a new position in Contineum Therapeutics in the 1st quarter valued at approximately $27,000. Norges Bank purchased a new position in Contineum Therapeutics in the 2nd quarter valued at approximately $674,000. Qube Research & Technologies Ltd acquired a new position in shares of Contineum Therapeutics in the second quarter worth $43,000. Finally, Jane Street Group LLC purchased a new stake in shares of Contineum Therapeutics during the second quarter worth $81,000.

Contineum Therapeutics Trading Down 5.0%

Shares of CTNM opened at $16.70 on Friday. The firm has a market capitalization of $628.27 million, a price-to-earnings ratio of -9.65 and a beta of 0.75. The firm’s fifty day simple moving average is $15.37 and its 200-day simple moving average is $14.06. Contineum Therapeutics, Inc. has a twelve month low of $8.60 and a twelve month high of $17.78.

Contineum Therapeutics (NASDAQ:CTNM) last issued its earnings results on Thursday, July 30th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. On average, analysts predict that Contineum Therapeutics, Inc. will post -1.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CTNM has been the topic of several analyst reports. Wall Street Zen upgraded Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Royal Bank Of Canada upped their price target on Contineum Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Friday, July 17th. Finally, Morgan Stanley lifted their price objective on Contineum Therapeutics from $14.00 to $16.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $20.25.

Contineum Therapeutics Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.